Milk free of A1 β-casein supports superior gains in cognition and quality of life, relative to conventional milk, in older adults with mild cognitive impairment
- PMID: 40373392
- PMCID: PMC12172951
- DOI: 10.1016/j.jnha.2025.100579
Milk free of A1 β-casein supports superior gains in cognition and quality of life, relative to conventional milk, in older adults with mild cognitive impairment
Abstract
Objectives: To determine whether the regular consumption of milk free from A1 β-casein (A1PF milk) improves cognitive performance to a greater extent than conventional milk, and if so, whether such improvements are associated with an increase in the serum titres of reduced glutathione (GSH).
Design: A multi-centre, double-blind, randomised controlled trial with two parallel arms, conducted from 7 March 2023 to 13 October 2023.
Setting: Two hospitals in Tianjin, China.
Participants: Volunteers (N = 96) diagnosed with mild cognitive impairment (MCI) and aged between 65 and 75 years.
Intervention: A1PF skim milk powder or conventional skim milk powder, diluted into liquid form (200 mL) and consumed twice daily for 90 days.
Measurements: The primary outcomes were cognitive performance (assessed with the Subtle Cognitive Impairment Test [SCIT]) and serum titres of GSH. Secondary outcomes included performance on two other cognitive tests, serum levels of 25-hydroxyvitamin D3, subjective quality of life (QoL), muscle strength (hand grip scale), faecal and blood inflammatory markers.
Results: Data from 91 participants were analysed (A1PF milk group: n = 45; conventional milk group: n = 46). A1PF milk improved performance on all three cognitive tests to a greater extent than conventional milk; however, this improvement was not associated with an increase in serum GSH. When compared with conventional milk, A1PF milk resulted in higher increases in serum levels of 25-hydroxyvitamin D3, greater subjective improvements in QoL and improved left hand grip strength. There were no between-group differences in inflammatory markers, calcium absorption or bone density markers.
Conclusion: Daily intake of A1PF milk for 90 days significantly improved cognition, QoL and muscle strength in a sample of older people with MCI. While these outcomes appear to be linked to increased serum titres of 25-hydroxyvitamin D3, further investigations are needed to confirm this association.
Clinical trial registration: NCT05741047 (clinicaltrials.gov).
Keywords: A1 protein-free milk; A2 milk; Beta casein; Handgrip strength.
Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of competing interest Stephen R. Robinson is a director of Neurotest Pty Ltd. This company markets the SCIT and also provides consultancy services for The a2 Milk Company. The other authors have no conflicts of interest to declare in relation to this study.
Figures


References
-
- Hanach N.I., McCullough F., Avery A. The impact of dairy protein intake on muscle mass, muscle strength, and physical performance in middle-aged to older adults with or without existing sarcopenia: a systematic review and meta-analysis. Adv Nutr. 2019;10(1):59–69. doi: 10.1093/advances/nmy065. - DOI - PMC - PubMed
-
- AOAC SMPR 2022.005 Standard method performance requirements (SMPRs®) for A1- and A2-Type β-Casein in Infant Formulas and Adult Nutritionals. Available at www.aoac.org/wp-content/uploads/2022/10/SMPR-2022_005.pdf.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical